Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
As many in the prostate cancer community will be aware, there has been a major battle ongoing over whether the drug bevacizumab (Avastin) should continue to be approved by the U.S. Food & Drug Administration (FDA) for the treatment of women with metastatic breast cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Centers for Medicare and Medicaid Services, CMS, coverage, off-label | Leave a Comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) – improves health outcomes for Medicare beneficiaries
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site